Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.
ChemMedChem
; 13(1): 30-36, 2018 01 08.
Article
em En
| MEDLINE
| ID: mdl-29205945
Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenaseâ
1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity inâ
vitro and inâ
vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
DNA
/
Antineoplásicos Alquilantes
/
Inibidores Enzimáticos
/
Indolamina-Pirrol 2,3,-Dioxigenase
/
Imunoterapia
/
Neoplasias
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
ChemMedChem
Assunto da revista:
FARMACOLOGIA
/
QUIMICA
Ano de publicação:
2018
Tipo de documento:
Article